A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Staphylococcal-protein-A (Primary)
- Indications Immune thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Protalex
- 07 Jun 2017 According to a Protalex media release, the company has started patients screening in the United Kingdom. With this expansion, the company now has more than 20 sites worldwide open for patient enrollment.
- 26 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 May 2018.
- 26 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.